Transforming growth factor (TGF-β) is associated with the progression of
glioblastoma multiforme (GBM)-the most malignant of
brain tumors. Since there is a structural homology between TGF-β and
human chorionic gonadotropin (hCG) and as both TGF-β and hCG-β are known regulators of oxidative stress and survival responses in a variety of
tumors, the role of TGF-β in the regulation of hCG-β and its consequences on redox modulation of
glioblastoma cells was investigated. A heightened hCG-β level was observed in GBM
tumors. TGF-β treatment increased hCG-β expression in
glioma cell lines, and this heightened hCG-β was found to regulate redox homeostasis in TGF-β-treated
glioma cells, as
siRNA-mediated knockdown of hCG-β (i) elevated
reactive oxygen species (ROS) generation, (ii) decreased
thioredoxin Trx1 expression and
thioredoxin reductase (TrxR) activity, and (iii) abrogated expression of TP53-induced glycolysis and apoptosis regulator (TIGAR). Silencing of hCG-β abrogated Smad2/3 levels, suggesting the existence of TGF-β-hCG-β cross-talk in
glioma cells.
siRNA-mediated inhibition of elevated TIGAR levels in TGF-β-treated
glioma cells was accompanied by an increase in ROS levels. As a
farnesyltransferase inhibitor,
Manumycin is known to induce
glioma cell apoptosis in a ROS-dependent manner, and we investigated whether
Manumycin could induce apoptosis in TGF-β-treated cells with elevated hCG-β exhibiting ROS-scavenging property.
Manumycin-induced apoptosis in TGF-β-treated cells was accompanied by elevated ROS levels and decreased expression of hCG-β, Trx1, Smad2/3, and TIGAR. These findings indicate the existence of a previously unknown TGF-β-hCG-β link that regulates redox homeostasis in
glioma cells.